Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 18, Issue 10, 1999, Pages 733-736

  Franco, J M ^a   Rubio, A ^a   Rey, C ^a   Leal, M ^a   Macias J ^a   Pineda, J A ^a   Sanchez B ^a   Sanchez Quijano A ^a   Nunez Roldan A ^a   Lissen, E ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; HLA DR ANTIGEN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0001607972     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050388     Document Type: Article

References (15)

1. 1. Copeland KFT, Heeney JL: T helper cell activation and human retroviral pathogenesis. Microbiological Reviews (1996) 60:722-742
2. 2. Stein DS, Lyles RH, Graham NMH, Tassoni CJ, Margolik JB, Phair JP, Rinaldo C, Detels R, Saah A, Bilello J: Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptor, neopterin and β2-microglobulin. Journal of Infectious Diseases (1997) 176:1161-1167
3. 3. Graham NM: The role of immunologic and viral markers in predicting clinical outcome in HIV infection. AIDS (1996) 10, Supplement 35:21-25
4. 4. Gowda SD, Stein BS, Mohagheghpour N, Benike CJ, Engleman EG: Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. Journal of Immunology (1989) 142:773-780
5. 5. Muro-Cacho CA, Pantaleo G, Fauci AS: Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. Journal of Immunology (1995) 154:5555-5566
6. 6. Rizzardi GP, Tambussi G, Barcellini W, Capiluppi B, Clerici E, Maestra LL, Lillo F, Pantaleo G, Lazzarin A: Soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors in primary HIV-infection: relationship with HIV-1, RNA, clinical outcome and early antiviral therapy. Journal of Biological Regulators and Homeostatic Agents (1997) 1:43-49
7. 7. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL: A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS (1996) 10:485-492
8. 8. Nokta M, Rossero R, Loesch K, Pollard RB: Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine and hydroxyurea. AIDS Research and Human Retroviruses (1997) 13:1633-1638
9. 9. Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR, Taylor P, Stevens CE: Processing and cryopreservation of placental / umbilical cord blood for unrelated bone marrow reconstitution. Proceedings of the National Academy of Sciences of the USA (1995) 92:10119-10122
10. 10. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report (1992) 41:1-19
11. 11. Haug CJ, Aukrust P, Lien E, Müller F, Espevik T, Frøland SS: Disseminated Mycobacterium avium complex infection in AIDS: immunopathogenic significance of an activated tumor necrosis factor system and depressed serum levels of 1,25 dihydroxyvitamin D. Journal of Infectious Diseases (1996) 173:259-262
12. 12. Frissen PHJ, Weverling GJ, Endert E, Jansen J, Saverwein HP, Lange JMA: Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology (1996) 12:482-488
13. 13. Marriott JB, Cookson S, Carlin E, Youle M, Hawkins DA, Nelson M, Pearson M, Vaughan AN, Gazzard B, Dalgleish AG: A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Research and Human Retroviruses (1997) 13:1625-1631
14. 14. Clerici M, Piconi S, Balotta C, Trabattoni D, Capetti A, Fusi ML, Ruzzante S, Longhi R, Colombo MC, Moroni M, Milazzo F: Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. Journal of Infectious Diseases (1997) 175:1210-1215
15. 15. del Real G, Llorente M, Bosca L, Hortelano S, Serrano A, Lucas P, Gomez L, Toran JL, Redondo C, Martinez AC: Suppression of HIV-1 infection in linomide-treated SCID-hu-PBL mice. AIDS (1998) 12:865-872